Please assess the completion status of the following clinical trial:

Trial Title: GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Documented HIV infection~* Plasma HIV-RNA \>= 1000 copies/mL~* Must be able to comply with protocol requirements~Exclusion Criteria:~* No prior use of PREZISTA (darunavir), TMC125, enfuvirtide, or tipranavir~* No currently active AIDS defining illness, Category C conditions according to the Center for Disease Control \[CDC\] Classification System for HIV Infection (1993) with the following exceptions, which must be discussed with the Sponsor prior to enrollment: stable cutaneous Kaposi's Sarcoma, Wasting syndrome due to HIV infection~* Not currently using an investigational drug~* Not pregnant or breastfeeding~* No Grade 3 or 4 laboratory abnormality as defined by DAIDS (Division of AIDS, National Institute of Allergy and Infectious Diseases).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): darunavir 600mg bid for 48 wks,ritonavir 100mg bid for 48 wks

Based on this trial design, predict the completion outcome and termination type (if applicable).